The Centers for Medicare & Medicaid Services (CMS) plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to reduce Medicare costs. This will result in varied impacts across diagnostic companies, with BillionToOne experiencing both positive and negative changes for its tests, while CareDx generally sees favorable or neutral outcomes for its core portfolio.
CMS is proposing significant changes to Medicare's clinical laboratory fee schedule, aiming to reduce payments by aligning them with private sector rates. This is a long-term initiative, phasing in reductions through 2029, with finalized rates expected in November 2026. For BillionToOne, the impact is mixed: its Northstar Response test sees a significant reimbursement increase, while its prenatal segment has both decreases and increases, leading management to view the net impact as neutral for prenatal and positive for oncology. CareDx, on the other hand, receives generally favorable updates, with AlloMap unchanged and AlloSure seeing a modest increase, and NavDx unaffected. This highlights that while the overall CMS policy aims for cost reduction, the specific impact on individual companies depends heavily on their proprietary tests and their exposure to different diagnostic categories. Traders should note the nuanced, company-specific effects rather than assuming a broad negative industry impact.